Watch, listen, and make treatment decisions as Douglas Ward, MD, leads you through this interactive presentation reviewing recent clinical trial data on the similarities and differences among PI-based antiretroviral regimens and the relevance of those data for individualizing first-line PI-based HIV treatment.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recount recent clinical trial data directly comparing the virologic efficacy of NNRTI- vs PI-based regimens for the initial treatment of HIV infection
- Compare and contrast virologic efficacy and toxicity associated with PI-based first-line regimens according to the latest data from randomized clinical trials
- Apply efficacy and safety data from comparative clinical trials of PI-based antiretroviral regimens as well as agent-specific factors such as pill burden and dosing schedule to the individualized selection of optimal PI-based regimens for the first-line treatment of HIV-infected patients
- Distinguish among deintensification strategies aimed at simplifying treatment or reducing toxicities with PI-based regimens